
Knockin Mice
Cyagen's knockin mice offer precise genetic modifications tailored to diverse research needs, including humanized and large-fragment knockins across C57BL/6 or BALB/c strains. These models enable effective disease modeling and functional studies by replicating human gene functions within a mouse, providing reliable, study-ready cohorts to fast-track preclinical research.

Guaranteed Results
Get animals or your money back.

Rapid Model Creation
Fast, precise genetic edits with guaranteed germline transmission.

Freedom to Operate
Patent dispute-free, enhancing drug development efficiency.
Overview
Workflow
FAQs
Overview
Precision Knockin Mouse Models
Cyagen offers precision-engineered knockin mouse models for advanced human gene function and disease research. Our comprehensive services range from point mutations to large-fragment knockins using state-of-the-art TurboKnockout® and Targeted Gene Editing technologies. Whether targeting the safe harbor locus (ROSA26/H11) or conducting any locus knockins, our models are tailored to enhance gene function studies and disease modeling in strains like C57BL/6 and BALB/c.
Trust Cyagen for efficient, cost-effective, and reliable knockin mouse model generation. We specialize in a broad range of project capabilities, handling knockin projects involving large fragments up to 300 kb. Each model is meticulously tailored to provide consistent and predictable results, ensuring alignment with your specific research needs.
Trust Cyagen for efficient, cost-effective, and reliable knockin mouse model generation. We specialize in a broad range of project capabilities, handling knockin projects involving large fragments up to 300 kb. Each model is meticulously tailored to provide consistent and predictable results, ensuring alignment with your specific research needs.

Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In

MouseAtlas Model Library
Search and access curated genetically engineered mouse strains

Turboknockout® Gene Editing
Fast-track your research with our efficient gene targeting service.

Targeted Gene Editing
AI-enhanced HDR technology for precise in vivo genome engineering

Rodent Breeding
Scalable colony expansion with full genotyping support

Cryopreservation & Recovery
Preserve and revive rodent strains on demand

Rodent Phenotyping
Full-spectrum analysis for rodents model
Workflow
Workflow and Delivery
Our refined workflow ensures the precise and timely creation of knockin
mouse models tailored to your research specifications. Utilize our
advanced TurboKnockout® and Targeted Gene Editing technologies to
achieve unparalleled accuracy and efficiency in gene targeting,
facilitating faster transitions from design to delivery.
TurboKnockout® Technology
Targeted Gene Editing Technology
Any Locus
ROSA26/H11
Point Mutation
TurboKnockout® Technology
TurboKnockout® Technology for Knockin Mice
Explore our efficient TurboKnockout® process tailored
for the precise delivery of knockin mouse models. Here's
an outline of our workflow:
| Stage | Description | Turnaround Time |
|---|---|---|
| Gene Targeting Strategy Design | Analyze target gene structure, adjacent genes, and existing models. Develop screening methods for targeted ES cells. | 1-4 days |
| Targeting Vector Construction | Clone necessary DNA fragments into the targeting vector. Validate construction through sequencing and restriction digest. | 6-8 weeks |
| Targeting in ES Cells | Electroporate TurboKnockout® ES cells, screen for targeted clones via PCR, and confirm by Southern blot and karyotyping. | 8-14 weeks |
| Mouse Production | Introduce targeted ES cells into host embryos, transfer to surrogate mothers, and genotype founders. Breeding to F1 generation. | 18-20 weeks |
Note:
Turnaround times exclude institutional approval and
shipping durations. For specific strain requests or
larger knockin fragments, please inquire about custom
solutions and pricing.
Targeted Gene Editing Technology for Knockin Mice at
Any Locus
Targeted Gene Editing Technology for Knockin Mice at Any
Locus
Discover Cyagen’s Targeted Gene Editing technology for
large-fragment and conditional knockin mouse models.
This versatile approach allows precise gene editing at
any genetic locus, making it ideal for diverse research
applications including disease modeling and functional
studies.
| Stage | Description | Turnaround Time |
|---|---|---|
| Strategy Design | Develop a nuclease-mediated strategy tailored to your gene of interest, including gRNA and donor vector design. | 1-4 days |
| Vector Construction | Construct the knockin vector based on client-approved strategy. Where needed, efficacy tests in cell culture can be conducted. | 6-8 weeks |
| Targeted Gene Editing Injection | Co-inject ribonucleoprotein (RNP) and the donor vector into fertilized mouse eggs, and implant to obtain founders. | 10-14 weeks |
| Founder Screening | Screen pups by PCR to identify those with successful knockin or floxed modifications. Where needed, Sanger sequencing can be conducted. | |
| Breeding Founders | Breed the founders to wildtype mice and genotype their offspring to ensure transmission of the knockin allele. | 12-16 weeks |
Note:
- Standard services cover knockin fragments up to 8 kb. Larger fragments may incur additional costs and time.
- All projects are conducted in the C57BL/6 strain by default, with options for other strains and rat models.
Targeted Gene Editing Technology for Knockin Mice at
ROSA26/H11 Locus
Targeted Gene Editing Technology for Knockin Mice at
ROSA26/H11 Locus
Delve into Cyagen’s Targeted Gene Editing technology
optimized for large-fragment knockin at the ROSA26/H11
locus, known for its reliability as a "safe harbor" site
that ensures stable gene expression without disrupting
endogenous genes. This method is ideal for researchers
aiming to achieve consistent and ubiquitous gene
expression across various applications.
| Stage | Description | Turnaround Time |
|---|---|---|
| Strategy Design | Develop a nuclease-mediated strategy tailored to your gene of interest, including gRNA and donor vector design. | 1-4 days |
| Vector Construction | Construct the ROSA26/H11 knockin vector based on client-approved strategy. Where needed, efficacy tests in cell culture can be conducted. | 4-7 weeks |
| Targeted Gene Editing Injection | Co-inject ribonucleoprotein (RNP) and the donor vector into fertilized mouse eggs at the ROSA26/H11 locus, followed by embryo implantation to obtain founders. | 10-14 weeks |
| Founder Screening | Screen pups by PCR to identify those with successful knockin at ROSA26/H11 locus. Where needed, Sanger sequencing can be conducted. | |
| Breeding Founders | Breed the founders to wildtype mice and genotype their offspring to ensure transmission of the knockin allele. | 12-16 weeks |
Note:
- Services include knockin fragment insertion up to 8 kb. Larger fragments may involve additional costs and time.
- Standard procedures are performed in the C57BL/6 strain, with options for other strains upon request.
Targeted Gene Editing Technology for Point Mutation
Mice
Targeted Gene Editing Technology for Point Mutation Mice
Explore Cyagen’s Targeted Gene Editing technology
tailored for point mutation knockin mice, ideal for
studying genetic disorders, rare diseases, and
functional genomics. This precise gene editing technique
allows for the introduction of specific nucleotide
changes that model human genetic variations accurately.
| Stage | Description | Turnaround Time |
|---|---|---|
| Strategy Design | Develop a nuclease-mediated strategy tailored to your gene of interest, including gRNA and donor oligo design. | 1-4 days |
| Targeted Gene Editing Injection | Co-inject ribonucleoprotein (RNP) and the donor oligo into fertilized mouse eggs, and implant to obtain founders. | 10-12 weeks |
| Founder Screening | Screen pups by PCR and Sanger sequencing to identify those with the correct point mutation knockin. | |
| Off-Target Analysis | Analyze potential off-target effects to ensure specificity of the gene edit. |
Note:
- Turnaround times do not include institutional approval processes or shipping.
- Services focus on knockin modifications in the C57BL/6 strain, with options for other strains.
FAQs
Frequently Asked Questions (FAQs)
What are knockin mice?
Knockin mice are genetically engineered models with precise modifications such as the insertion of human genes or point mutations into their genome. These models are vital for studying human gene function, disease mechanisms, and testing therapeutic interventions in a controlled, predictable manner.
How to Generate Knock-in Mice?
Generating knock-in (KI) mice involves inserting a specific DNA sequence into a targeted genomic locus. The process generally follows these 4 steps:
Design & Vector Construction: Create a donor DNA template containing your gene of interest flanked by homology arms (sequences matching the target site).
Gene Editing Technology:
ES Cell Targeting: Traditional method involving homologous recombination in embryonic stem cells for complex or large insertions.
Embryo Manipulation: Inject targeted ES cells into blastocysts, then implant them into surrogate mothers.
Screening & Breeding: Genotype the offspring via PCR/Sequencing to confirm integration and breed them to ensure germline transmission.
Design & Vector Construction: Create a donor DNA template containing your gene of interest flanked by homology arms (sequences matching the target site).
Gene Editing Technology:
ES Cell Targeting: Traditional method involving homologous recombination in embryonic stem cells for complex or large insertions.
Embryo Manipulation: Inject targeted ES cells into blastocysts, then implant them into surrogate mothers.
Screening & Breeding: Genotype the offspring via PCR/Sequencing to confirm integration and breed them to ensure germline transmission.
What is the primary difference between knockout and knockin mouse models?
At its simplest, knockout (KO) is about "loss of function," while knockin (KI) is about "gain or alteration of function." Both leverage precise genome editing but serve different research purposes:
Knockout (KO): Involves the inactivation or deletion of a specific gene. It is used to study the biological necessity of a gene by observing what happens when its function is completely removed.
Knockin (KI): Involves the insertion of a specific exogenous DNA sequence (such as a humanized gene, a reporter like GFP, or a point mutation) into a targeted locus. It is used to model human diseases or track gene expression.
Knockout (KO): Involves the inactivation or deletion of a specific gene. It is used to study the biological necessity of a gene by observing what happens when its function is completely removed.
Knockin (KI): Involves the insertion of a specific exogenous DNA sequence (such as a humanized gene, a reporter like GFP, or a point mutation) into a targeted locus. It is used to model human diseases or track gene expression.
What types of diseases can be studied using knock-in (KI) mouse models?
Knock-in (KI) mice are indispensable in biomedical research because they can mimic specific genetic alterations found in human patients. Unlike knockout mice, which primarily study "loss-of-function," knock-in models allow for the study of "gain-of-function" or "change-of-function" mutations.
Key disease areas studied using KI models include:
Rare Genetic Disorders: Modeling specific human point mutations (e.g., Single Nucleotide Polymorphisms) to study conditions like Cystic Fibrosis or Duchenne Muscular Dystrophy (DMD).
Neurodegenerative Diseases: Inserting human genes associated with Alzheimer’s, Parkinson’s, or Huntington’s disease (e.g., humanized MAPT or APP genes) to study protein aggregation and neuronal decay.
Cancer & Oncology: Studying the effects of specific oncogenic mutations (e.g., KRAS or p53 point mutations) or creating reporter strains to track tumor growth and metastasis in vivo.
Cardiovascular Diseases: Modeling hereditary cardiomyopathies by introducing specific contractile protein mutations.
Key disease areas studied using KI models include:
Rare Genetic Disorders: Modeling specific human point mutations (e.g., Single Nucleotide Polymorphisms) to study conditions like Cystic Fibrosis or Duchenne Muscular Dystrophy (DMD).
Neurodegenerative Diseases: Inserting human genes associated with Alzheimer’s, Parkinson’s, or Huntington’s disease (e.g., humanized MAPT or APP genes) to study protein aggregation and neuronal decay.
Cancer & Oncology: Studying the effects of specific oncogenic mutations (e.g., KRAS or p53 point mutations) or creating reporter strains to track tumor growth and metastasis in vivo.
Cardiovascular Diseases: Modeling hereditary cardiomyopathies by introducing specific contractile protein mutations.
Which methodologies are currently used to create precise knock-in mouse models?
The generation of knock-in (KI) mice relies on the precise insertion of exogenous DNA into a specific genomic locus. To ensure genetic stability and germline transmission, researchers primarily utilize the following advanced gene-targeting strategies:
1. Traditional ES Cell-Based Gene Targeting
This remains the "gold standard" for complex large-fragment insertions.
Mechanism: A targeting vector is introduced into Embryonic Stem (ES) cells via electroporation. Through the natural process of homologous recombination, the DNA sequence in the vector replaces the corresponding sequence in the cell's genome.
Process: Successfully targeted ES cells are selected and injected into blastocysts, which are then transferred to surrogate mothers to produce chimeric mice.
Best For: Projects requiring high genomic integrity, large-scale humanization, or conditional gene modifications (e.g., Cre-LoxP systems).
2. Cyagen’s Proprietary TurboKnockout® Technology
To overcome the long timelines associated with traditional ES cell methods, Cyagen developed the TurboKnockout® platform.
The Cyagen Advantage: This technology optimizes the standard ES cell-based approach by utilizing a unique cell-mediated logic that can bypass the chimera stage. It allows for the generation of heterozygous F1 mice directly.
Benefits: It reduces the project timeline to as little as 6–8 months while maintaining the extreme precision and stability of ES cell targeting.
Best For: Complex preclinical models that require both speed and absolute accuracy in genomic positioning.
1. Traditional ES Cell-Based Gene Targeting
This remains the "gold standard" for complex large-fragment insertions.
Mechanism: A targeting vector is introduced into Embryonic Stem (ES) cells via electroporation. Through the natural process of homologous recombination, the DNA sequence in the vector replaces the corresponding sequence in the cell's genome.
Process: Successfully targeted ES cells are selected and injected into blastocysts, which are then transferred to surrogate mothers to produce chimeric mice.
Best For: Projects requiring high genomic integrity, large-scale humanization, or conditional gene modifications (e.g., Cre-LoxP systems).
2. Cyagen’s Proprietary TurboKnockout® Technology
To overcome the long timelines associated with traditional ES cell methods, Cyagen developed the TurboKnockout® platform.
The Cyagen Advantage: This technology optimizes the standard ES cell-based approach by utilizing a unique cell-mediated logic that can bypass the chimera stage. It allows for the generation of heterozygous F1 mice directly.
Benefits: It reduces the project timeline to as little as 6–8 months while maintaining the extreme precision and stability of ES cell targeting.
Best For: Complex preclinical models that require both speed and absolute accuracy in genomic positioning.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

